vTv Therapeutics Inc. (NASDAQ:VTVT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
VTVT has been the topic of a number of other reports. HC Wainwright initiated coverage on vTv Therapeutics in a research note on Monday, September 26th. They issued a “buy” rating and a $13.00 target price on the stock. Canaccord Genuity reissued a “buy” rating and issued a $15.00 target price on shares of vTv Therapeutics in a research note on Friday, August 19th.
vTv Therapeutics (NASDAQ:VTVT) traded up 0.349% during trading on Wednesday, hitting $6.894. 3,151 shares of the company’s stock traded hands. vTv Therapeutics has a 52-week low of $4.84 and a 52-week high of $8.22. The company’s 50 day moving average price is $6.46 and its 200 day moving average price is $5.91. The company’s market cap is $66.80 million.
vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Tuesday, August 16th. The company reported ($0.47) EPS for the quarter. Analysts expect that vTv Therapeutics will post ($1.61) earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in VTVT. State Street Corp increased its position in shares of vTv Therapeutics by 10.9% in the first quarter. State Street Corp now owns 61,239 shares of the company’s stock worth $316,000 after buying an additional 6,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of vTv Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 34,884 shares of the company’s stock worth $180,000 after buying an additional 822 shares during the last quarter. Kennedy Capital Management Inc. acquired a new position in shares of vTv Therapeutics during the first quarter worth about $282,000. Ameriprise Financial Inc. increased its position in shares of vTv Therapeutics by 17.2% in the second quarter. Ameriprise Financial Inc. now owns 161,484 shares of the company’s stock worth $936,000 after buying an additional 23,705 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of vTv Therapeutics by 4.1% in the second quarter. Vanguard Group Inc. now owns 288,146 shares of the company’s stock worth $1,671,000 after buying an additional 11,428 shares during the last quarter. 12.84% of the stock is currently owned by hedge funds and other institutional investors.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.